69 累计需求单数
¥3,113,910.0 累计需求金额
0 违规次数

初奖1200000人民币,寻找一种可以与D-葡萄糖结合的分子

悬赏
未托管赏金
¥0.00
  1. 发布需求
  2. 药智客交稿
  3. 任务主选稿中
  4. 验收与付款
  1. 任务结束
任务结束
交易模式:
单人中标
赏金分配:
一人独享赏金,¥0
具体要求:
控制体内血糖水平是成功治疗许多疾病的关键,如糖尿病。 因此, Novo Nordisk公司正在寻找新的小分子,它可以于D-葡萄糖的生理集合密切结合 (持续的取代,Kd,低毫摩尔范围)
悬赏须提交概念性实验数据报告和样品,Novo Nordisk公司将决定最终得奖者,并颁发起始奖金200000美金。
另外Novo Nordisk公司将提议基于里程碑式的合约,如果分子式在未来悬赏中得到成功研发,将会得到二次奖项。

悬赏截止时期2017年1月9日,
投标网址:https://www.innocentive.com/ar/projectRoom/index?challenge=9933823

原文:

Novo Nordisk Challenge: Design and Synthesis of a Small Molecule Glucose Binder
 
TAGS: 
Chemistry, Life Sciences, Royal Society of Chemistry, RTP
AWARD: $200,000 USD  |  DEADLINE: 1/09/17  |  ACTIVE SOLVERS: 145  |  POSTED: 3/30/16
The control of glucose levels in the body is key for successful treatment of many disease states such as diabetes. Hence, Novo Nordisk is looking for novel small molecules that can bind with affinities matching the physiological concentrations of D-glucose (displacement constant, Kd, in the low millimolar range). 
This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery. Additionally, the Challenge has the following unique features.Please read carefully the Challenge-Specific Agreement.
•	Solvers are asked to prepare the compound and perform binding affinity assays to glucose in aqueous solution under conditions described in the Challenge Description. The compounds must also be supplied to Novo Nordisk in sufficient amounts to reproduce the results. Upon experimental validation of the results, Novo Nordisk will make an award (‘Initial Transfer Fee’) of $200,000 to the best solution as solely determined by the Seeker, according to the Challenge requirements. The Awarded Solver grants Novo Nordisk an exclusive license under the terms described in the Challenge-Specific Agreement.
•	Additionally, Novo Nordisk will offer a milestone-based agreement to the Solver, establishing the terms of payment of anadditional award (‘Secondary Award’), should the small molecule be successful in its development post-Challenge(‘Second Evaluation Period’), in exchange for the assignment of exclusive IP rights to the Seeker.
Source: InnoCentive      Challenge ID: 9933823
 
 
Sign Agreement For This Challenge
By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge.
Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records
InnoCentive RTP Challenge-Specific Agreement
Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Challenge only, as permitted in the Terms of Use. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them.
If you click \\\\\\\\"I agree\\\\\\\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\\\\\\\"CSA\\\\\\\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge and in addition to your agreement to abide by the Terms of Use when you registered as a Solver. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply.
1.	Your Responsibility to Avoid Obstacles. InnoCentive needs to know that if you solve the InnoCentive Challenge there will not be any legal obstacles to completing the license or sale of your rights to InnoCentive and subsequently to Seeker, which is the only way that you can receive the Initial Transfer Fee or the Secondary Award. You agree to be responsible for avoiding any legal obstacles to transferring the Proposed Solution and the associated work product (altogether, the “Work Product”) as well as all related Intellectual Property (altogether, the \\\\\\\\"Solution IP\\\\\\\\") if you submit a Proposed Solution chosen as a winning Solution. You will not receive an Initial Transfer Fee or Secondary Award if you cannot transfer the Solution IP.
2.	Your Guarantee. You agree that if and when the time comes to assign and transfer the Solution IP, you will give a guarantee (the \\\\\\\\"Guarantee\\\\\\\\") that the assignment and transfer is lawful in exchange for the one-time payment of the Initial Transfer Fee or the Secondary Award to you alone, and that no consents, approvals or contracts that you did not already have before starting the InnoCentive Challenge are necessary from or with anyone else, such as:
a.	Your employer;
b.	Any former employer or other entity you are or have been associated with or have a contract with regarding Intellectual Property you develop;
c.	Anyone collaborating with you on the development of the Solution IP;
d.	Anyone else whose Intellectual Property you use or incorporate in the Solution IP;
e.	Any government official, regulatory body or other authority (for example, if any of the Solution IP is within the scope of a technology export control law in your country prohibiting its transfer to InnoCentive in the United States, or if the required assignments or licenses of the Solution IP are otherwise subject to public registration, review and/or approval)
f.	The holder of any lien (for example, if a bank or other creditor has obtained a mortgage or security interest in any of the Solution IP);
g.	Anyone who may be entitled to royalties or other payments relating to any of the Solution IP either by law or contract.
3.	Your Obligations to Protect Potential Solution IP. In order to be eligible for an Initial Transfer Fee or the Secondary Award, during the period from when you begin work on the InnoCentive Challenge until the expiration of the First Evaluation Period or the Second Evaluation Period, as applicable, as set forth in the Challenge Statement, you shall not:
a.	Grant away any rights in the Work Product, Intellectual Property or Proposed Solution you are developing (\\\\\\\\"Potential Solution IP\\\\\\\\"), or do anything else that would prevent you from granting the rights to Seeker in accordance with this CSA;
b.	Reveal to any third party, except on terms of strict confidentiality, any information that relates to Potential Solution IP or do anything else likely to impair any of the Potential Solution IP; or
c.	Do anything that would cause the failure of your Guarantee.
4.	Exclusivity Period. By submitting your Proposed Solution you agree to grant to InnoCentive and the Seeker for a period of 60 days from the later of the deadline set forth in the InnoCentive Challenge Statement or Seeker’s receipt of a sample of the Proposed Solution (the \\\\\\\\"First Evaluation Period\\\\\\\\") an exclusive, worldwide license to use, copy, distribute and create derivative works of the Proposed Solution and Solution IP for purposes of review, analysis and testing the Proposed Solution. If Seeker within the First Evaluation Period notifies InnoCentive of any Proposed Solution that Seeker has determined shall be a winning Solution that will be awarded the Initial Transfer Fee, you further grant to InnoCentive and Seeker (i) an exclusive, fully-paid license to use, copy, distribute and create derivative works of the Proposed Solution and Solution IP for its internal testing and non-commercial use for a period of 12-36 months from payment of the Initial Transfer Fee (the “Second Evaluation Period”), and (ii) an exclusive option (the “Option”) to negotiate with the Solver in good faith to fully acquire any and all exclusive rights to the Proposed Solution and Solution IP by paying to you the Secondary Award (collectively, these exclusive rights and the option are referred to as the “Exclusive Rights”). The Second Evaluation Period will initially be 12 months, but Seeker shall have the option to extend the Second Evaluation Period twice, each time by additional 12 months, providing for a maximum period of 36 months. If Seeker decides to extend the Second Evaluation Period beyond the initial 12 months, Seeker will pay to Solver a one-time only “Secondary Evaluation Period Extension Fee” of [$20,000]. If Seeker decides not to use the Option and pay the Secondary Award, the “Secondary Evaluation Period Extension Fee” will not be refundable. If Seeker decides to use the Option and pays to Solver the Secondary Award, the option payment will be deducted from the Secondary Award.  
InnoCentive will make reasonable efforts to transmit relevant Proposed Solutions to Seeker, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution submitted in response to an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning Work Product and your Proposed Solution to InnoCentive or the Seeker during the First Evaluation Period and Second Evaluation Period, if requested. By granting the Exclusive Rights you agree that during the First Evaluation Period and Second Evaluation Period (and thereafter, if the Option is exercised), you are prohibited from (x) using, the Proposed Solution or the Solution IP or (y) disclosing to or granting or assigning or transferring any rights to a third party to use the Proposed Solution or the Solution IP for any purpose, including the application for patents or similar intellectual property rights.
5.	Acceptance of Proposed Solution and Transfer of Intellectual Property. InnoCentive will notify you within a commercially reasonable period of time after the deadline set forth in the InnoCentive Challenge Statement and before the expiry of the First Evaluation Period whether a Seeker accepts your Proposed Solution and wishes to exercise its right to extend the evaluation process into the Second Evaluation Period (\\\\\\\\"Acceptance\\\\\\\\"). For purposes of this Agreement, \\\\\\\\"Acceptance\\\\\\\\" shall mean the selection of your Proposed Solution by the Seeker as meeting the Solution Acceptance Criteria as set forth in the InnoCentive Challenge Statement. The Seeker has absolute and sole discretion to determine whether to Accept your Proposed Solution, or any Proposed Solution, and whether to make an Initial Transfer Fee or the Secondary Award, multiple Initial Transfer Fee or the Secondary Awards or any Initial Transfer Fee or the Secondary Award. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver, if any. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver, if any. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\\\\\\\'s failure to win an award. The meeting of the Solution Acceptance Criteria does not mean that the Proposed Solution will be Accepted by a Seeker. In the event that your Proposed Solution is not Accepted within the First Evaluation Period, the Exclusive Rights will terminate without further notice to you. Upon Acceptance of your Proposed Solution by a Seeker and payment of a Secondary Award to you (see \\\\\\\\"Payments\\\\\\\\"), you hereby assign and convey to Seeker all rights, title, and interests in and to the Proposed Solution, the Solution IP and any Work Product that are related to the InnoCentive Challenge, and you retain no rights to the Proposed Solution, the Solution IP or the Work Product insofar as they are related to the InnoCentive Challenge. In the event that the Work Product cannot be assigned and conveyed under statutory law, you herewith grant to Seeker a worldwide, unlimited, perpetual, irrevocable, and exclusive license to use, make, have made, market, copy, modify, lease, sell, distribute, and create derivative works of the Work Product (all such rights collectively referred to as \\\\\\\\"Intellectual Property\\\\\\\\") . If you utilize any processes in development of the Work Product which are the subject of patent rights owned by you, you agree to grant to InnoCentive a worldwide, non-exclusive, perpetual, royalty-free right and license to practice any patented processes used in the Work Product, including the right to assign the foregoing license to Seekers. Furthermore, you agree that you will, during the term of this Agreement and at any time thereafter, execute all papers and do all things deemed necessary by InnoCentive or a Seeker to ensure that InnoCentive and the Seeker acquires all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, including the rights to all Intellectual Property embodied therein, and that ensures that all such rights are transferred to Seeker. Such cooperation and execution shall be performed without additional compensation to you; provided, however, InnoCentive shall reimburse you for reasonable out-of-pocket expenses incurred at the specific request of InnoCentive. Upon payment of the Secondary Award, or termination of the Exclusive Rights for any reason, there will be no further obligations between you and InnoCentive or the Seeker with respect to the Proposed Solution, the Work Product, or the InnoCentive Challenge, except for the limitations on use and disclosure described under \\\\\\\\"Confidentiality\\\\\\\\", below.
6.	Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an “Initial Transfer Fee” or a \\\\\\\\"Secondary Award\\\\\\\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of any of the awards, a \\\\\\\\"Revised Award Amount\\\\\\\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after occurrence of each of the following:  1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of award payment from the Seeker. Payment of any award is conditioned upon your cooperation with InnoCentive\\\\\\\'s verification procedures. The award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any award, or any part of any award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on awards shall be your sole responsibility.
7.	Escrows. The transfers of Solution IP and the Initial Transfer Fee or Secondary Award or any Revised Award Amount (as determined by Seeker) will be in escrow as follows:
a.	Your transfer of the Solution IP will be to InnoCentive as escrow agent for the Seeker. The Solution IP will be released from this escrow and transferred to the Seeker upon the occurrence of (a) the completion of InnoCentive\\\\\\\'s verification of you; (b) the Seeker\\\\\\\'s payment of the Initial Transfer Fee or Secondary Award to InnoCentive; and (c) the Seeker\\\\\\\'s payment of any other fees of InnoCentive pursuant to the separate agreement between Seeker and InnoCentive.
b.	The Seeker\\\\\\\'s payment of the Initial Transfer Fee or Secondary Award will be to InnoCentive as escrow agent for you. The Initial Transfer Fee or Secondary Award will be released from this escrow and transferred to you as soon as payment is due to you.
8.	Confidentiality. During the term of this Agreement and at all times thereafter, you shall not disclose to any third party nor use for any purpose other than for the performance of this Agreement, any Confidential Information (as defined below) without the express written consent of the owner of the Confidential Information. These confidentiality obligations shall not apply to Confidential Information which: (a) is in the public domain, or which was publicly known or available on the date you originally accepted this Agreement (\\\\\\\\"Effective Date\\\\\\\\"); or (b) after the Effective Date becomes available to the public in a manner not involving a breach of any duty under this Agreement. Nothing herein shall preclude the ultimate disclosure of any information required by law. \\\\\\\\"Confidential Information\\\\\\\\" includes:
•	All information set forth in the password protected areas of the Service (\\\\\\\\"Service Information\\\\\\\\"), (the presentation of Service Information via the Service shall not be deemed to be a public disclosure for purposes of this Agreement and shall not operate as an exclusion from Confidential Information); and
•	During the First Evaluation Period or Second Evaluation Period and after Acceptance and exercise of an Option relating to a InnoCentive Challenge, any Work Product, Solution IP or Proposed Solution relating to said InnoCentive Challenge.
The same restrictions on disclosure and use of Confidential Information described in this Section shall apply to the use or disclosure by InnoCentive and Seekers of any Work Product, Solution IP or Proposed Solution during the Exclusivity Period and, if the Proposed Solution is not accepted, thereafter, unless the Proposed Solution, Solution IP or Work Product can be shown by business records of Seeker or InnoCentive to (1) have been known to them previously; (2) is independently created by personnel of Seeker or InnoCentive who had no access to the Proposed Solution, Solution IP or the Work Product; or (3) is subject to the exceptions to Confidentiality in (a) or (b) of this section; provided, however, notwithstanding the foregoing, nothing in this Solver Agreement shall prevent a Seeker from utilizing a winning Solution, for which a Secondary Award has been paid, to the extent that a winning Solution and any rejected Proposed Solution contain overlapping Work Product or Solution IP.
9.	Notwithstanding anything herein to the contrary, you recognize that other persons may have provided Seeker or others, or made public, or may in the future submit, or make public, materials that are the same or similar to your Proposed Solution. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\\\\\\\'s use of such materials.
10.	General Conditions: InnoCentive and/or Seeker has the right to verify each Solver\\\\\\\'s eligibility and compliance with this CSA, and to eliminate any Solver, or terminate any Solver\\\\\\\'s registration on the basis of its investigation. Participation is conditioned on providing the data required on the online registration form. Personal data will be processed in accordance with InnoCentive\\\\\\\'s Privacy Policy which can be located athttp://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. Seeker reserves the immediate right to disqualify any Solver who, in InnoCentive\\\\\\\'s sole discretion: (i) is not in compliance with the Terms of Use or this CSA, (ii) tampers with the submission process, the Challenge, or the Website; or (iii) is acting in an uncooperative, unsportsmanlike, disruptive, abusive, or threatening manner.
11.	Third Party Beneficiary. You and InnoCentive acknowledge and agree that any Seeker shall be a third- party beneficiary of this Agreement, and each shall have the right to assert and enforce the provisions of this Agreement directly on its own behalf.
12.	Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls.

				
2016-05-18 17:05
0条新稿件,点击看看
还没有人交稿哦!
赶快点击交稿吧~

当前为付费需求,赏金分配方式:一人独享赏金。

任务主在众多备选稿件中选择最满意的稿件,支付赏金。

托管赏金,保障各方权益:

任务主把所发需求的悬赏金托管到药智网指定账户,以激发众多药智客的参与热情,保障任务主尽快征集到满意稿件;

同时,赏金托管也是为了保障参与挑战的药智客的正当权益。

流程说明:

发布需求

点击“发布需求”按钮,按照流程引导,将需求详情、具体要求描述清楚,发布到药智网的药智汇平台。

托管赏金

为征集到满意稿件,任务主须做好“赏金预算”,并将赏金托管到药智网指定账户,打消药智客的顾虑,激励药智客积极参与需求挑战。

药智客参与

任务主托管赏金后,所发布的需求显示“赏金已托管”字样。只有托管了悬赏金的需求,能够鼓舞众多的药智客参与,获取到满意的稿件!

选择满意稿件

任务主在众多参与者提交的稿件中,选择符合任务主需求的稿件。再通过互动,选择任务主最满意的稿件,并确定其为中标稿件。

验收与付款

中标稿件提交任务主验收。任务主在验收/验证期内,完成验收/验证工作。对合格稿件,通知药智网支付佣金。

评价

双方可以针对本次交易各自的表现进行评价,评价结果将影响各自的信用度和能力值。

类似的需求

    加载数据中...

该需求者还有这些需求

    加载数据中...

推荐需求

    加载数据中...
感兴趣,就投稿吧!投的越早,中标几率就越大! 收藏
扫一扫,关注药智汇微信
及时获得最新药智汇信息

2014 药智再发力 我们换装了!!

为了让您有更好的体验,药智对用户体系和产品进行了全新升级!

我要看看